Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Enrolling by invitation · Phase 2 · NCT03999801

Conditions: Neovascular Age-related Macular Degeneration, Wet Macular Degeneration

Research payments reported, 2025: $111,076
U.S. investigators named: 36
Sites paid: 32
Planned or actual enrollment: 865

About the trial

Sponsor: AbbVie
Tested: RGX-314 (genetic)
Dates: Started 2019-05-31; completion 2028-12
Results posted: Not yet

This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study in which they received a single subretinal administration of RGX-314 in their study eye. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early termination visit in the previous (parent) clinical study. Participants will be followed for up to 5 years post-RGX-314 administration (inclusive of the parent study). After enrollment and a 6-month follow-up visit, participants will attend at least annual study visits through the e…

From ClinicalTrials.gov, last updated 2024-06-17. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $111,076 in research payments for this study in 2025 (65 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it